Remove Genetics Remove Genotype Remove Marketing
article thumbnail

FDA grants approval for bluebird’s Zynteglo to treat beta-thalassemia

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for bluebird bio ’s Zynteglo (betibeglogene autotemcel, beti-cel) for the treatment of the underlying genetic cause of beta?thalassemia 0 genotypes. thalassemia in adult and paediatric patients.

article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates. The logical extension to this kind of approach is treating individual patients, with their individual genetic makeup.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Pharmacogenomics may finally realise its promise

pharmaphorum

The participants undergo monitoring for genetic variations that could potentially negatively impact their reaction to therapies. The program is aiming to genotype roughly 150,000 participants over the next few years to demonstrate the impact personalised testing can have on a large scale. About the Author.

article thumbnail

LabCorp Backs Resolution Bioscience’s Liquid Biopsy Test for NSCLC

XTalks

Based on the genetic biomarker(s) identified, the most effective therapy targeting the specific molecular marker can be selected. The liquid biopsy will therefore help personalize medicines for patients based on the molecular features of their disease.

Gene 105
article thumbnail

Molecular Diagnostic Tests: The Unsung Hero of Precise Clinical Decision Making

Roots Analysis

These diagnostic solutions are essential for detecting and monitoring diseases, identifying genetic abnormalities, and guiding personalized treatment plans. Molecular diagnostic solutions are pivotal across various medical fields, including oncological disorders, infectious diseases, genetic testing, and personalized medicine.

article thumbnail

Roche signs definitive share purchase agreement with long-term partner TIB.

The Pharma Data

TIB Molbiol is a biotech company that has supplied the global market with reagents for research and medical diagnostics for over 30 years. To support customers performing human genotyping, TIB Molbiol provides custom made LightSNiP assays for SNP analysis. The majority of assays are used to test for infectious diseases.

article thumbnail

Navigating Neuroscience Trials: Biomarkers, Imaging and CRO Strategies

XTalks

The worldwide market for neurology clinical trials stood at a valuation of $5.24 Moreover, combining biofluid analytes with molecular pathology (genetic biomarkers) allows for the classification and differentiation of neurodegenerative diseases. billion in 2022. It’s projected to grow at a compound annual growth rate (CAGR) of 5.6

Trials 111